NCT06583330View on ClinicalTrials.gov

A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery

NANot yet recruitingINTERVENTIONAL

Enrollment

1,448

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions

Colorectal SurgeryVTE (Venous Thromboembolism)

Interventions

DRUG

Low Molecular Weight Heparin (dalteparin)

All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.

All Listed Sponsors

lead

Beijing Friendship Hospital

OTHER

NCT06583330 - A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery | Biotech Hunter | Biotech Hunter